Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma

NCT05055323 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT05055323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05055323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma
Lead sponsor
Thomas Jefferson University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 29, 2021
Completion date
December 31, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic ductal adenocarcinoma, stage 0 pancreatic cancer ajcc v8, stage i pancreatic cancer ajcc v8, stage ia pancreatic cancer ajcc v8, stage ib pancreatic cancer ajcc v8, stage ii pancreatic cancer ajcc v8, stage iia pancreatic cancer ajcc v8, stage iib pancreatic cancer ajcc v8